Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités

Keymed Biosciences reported 1H26 (ended 30 June 2026) total revenue of 617 million RMB, with its flagship product Kangyueda cited as generating revenue (figures not provided in the excerpt). The release appears primarily informational, with no profit, growth, or guidance numbers included here. Overall, impact is likely limited absent further details on margins and outlook.